You are here

Category: Most Recent

Endoscopic alterations in Peyer’s patches in patients with ulcerative colitis: A prospective, multicenter study.

ibdwatch

Endoscopic alterations in Peyer’s patches in patients with ulcerative colitis: A prospective, multicenter study. J Gastroenterol Hepatol. 2019 Nov 16;: Authors: Hiyama S, Iijima H, Sakakibara Y, Yamada T, Mukai A, Otake Y, Yamaguchi T, Araki M, Kawai S, Tsujii Y, Inoue T, Hayashi Y, Shinzaki S, Takehara T Abstract BACKGROUND AND AIM: Peyer’s patches (PPs) play a major role in intestinal mucosal immunity; however, their role in ulcerative colitis (UC) is not well investigated. We evaluated endoscopic features of PPs on narrow-band imaging with magnifying endoscopy (NBI-ME) and investigated…

Read More

Cost-effectiveness and Clinical Outcomes of Early Anti-Tumor Necrosis Factor-α Intervention in Pediatric Crohn’s Disease.

ibdwatch

Related Articles Cost-effectiveness and Clinical Outcomes of Early Anti-Tumor Necrosis Factor-α Intervention in Pediatric Crohn’s Disease. Inflamm Bowel Dis. 2019 Nov 15;: Authors: Bashir NS, Walters TD, Griffiths AM, Ito S, Ungar WJ Abstract BACKGROUND: Anti-tumor necrosis factor-α (anti-TNF-α) treatments are increasingly used to treat pediatric Crohn’s disease, even without a prior trial of immunomodulators, but the cost-effectiveness of such treatment algorithms has not been formally examined. Drug plan decision-makers require evidence of cost-effectiveness to inform funding decisions. The objective was to assess the incremental cost-effectiveness of early intervention with…

Read More

The Incidence and Prevalence of Anxiety, Depression, and Post-traumatic Stress Disorder in a National Cohort of US Veterans With Inflammatory Bowel Disease.

ibdwatch

Related Articles The Incidence and Prevalence of Anxiety, Depression, and Post-traumatic Stress Disorder in a National Cohort of US Veterans With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 Nov 15;: Authors: Thakur ER, Sansgiry S, Kramer JR, Waljee AK, Gaidos JK, Feagins LA, Govani SM, Dindo L, El-Serag HB, Hou JK Abstract BACKGROUND: Patients with inflammatory bowel disease (IBD) are more susceptible to mental health problems than the general population; however, temporal trends in psychiatric diagnoses’ incidence or prevalence in the United States are lacking. We sought to identify these…

Read More

Reply – Associations between drug exposure and outcomes in patients with primary sclerosing cholangitis and inflammatory bowel disease.

ibdwatch

Reply – Associations between drug exposure and outcomes in patients with primary sclerosing cholangitis and inflammatory bowel disease. Clin Gastroenterol Hepatol. 2019 Nov 12;: Authors: Bergquist A, Stokkeland K, Bottai M, Söderberg-Löfdal K PMID: 31730911 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31730911?dopt=Abstract

Read More

Cannabis Use in Persons With Inflammatory Bowel Disease and Vulnerability to Substance Misuse.

ibdwatch

Cannabis Use in Persons With Inflammatory Bowel Disease and Vulnerability to Substance Misuse. Inflamm Bowel Dis. 2019 Nov 14;: Authors: Hansen TM, Sabourin BC, Oketola B, Bernstein CN, Singh H, Targownik LE Abstract BACKGROUND: It is unknown whether cannabis users self-medicating their inflammatory bowel disease (IBD) symptoms are more likely to have comorbid mental health or personality risk factors associated with an increased potential for substance misuse compared with recreational cannabis users. METHODS: We surveyed individuals with IBD about their cannabis use, their mental health symptoms, and personality risk factors…

Read More

Clostridium Difficile and Increased Risk of Surgery in Crohn’s Disease. Can Early Microbial Signatures Forecast Risk of Disease Progression?

ibdwatch

Clostridium Difficile and Increased Risk of Surgery in Crohn’s Disease. Can Early Microbial Signatures Forecast Risk of Disease Progression? Inflamm Bowel Dis. 2019 Nov 14;: Authors: Goyal A PMID: 31725870 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31725870?dopt=Abstract

Read More

Microbial Shifts and Shorter Time to Bowel Resection Surgery Associated with C. difficile in Pediatric Crohn’s Disease.

ibdwatch

Microbial Shifts and Shorter Time to Bowel Resection Surgery Associated with C. difficile in Pediatric Crohn’s Disease. Inflamm Bowel Dis. 2019 Nov 14;: Authors: Hellmann J, Andersen H, Fei L, Linn A, Bezold R, Lake K, Jackson K, Meyer D, Dirksing K, Bonkowski E, Ollberding NJ, Haslam DB, Denson L Abstract BACKGROUND: Clostridioides difficile infection and colonization are common in pediatric Crohn’s disease (CD). Our aims were to test the relationship between C. difficile positivity and bowel resection surgery and to characterize microbial shifts associated with C. difficile carriage and…

Read More

Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis.

ibdwatch

Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis. Dig Dis Sci. 2019 Nov 13;: Authors: Bossa F, Biscaglia G, Valvano MR, Costantino G, Lauria A, Clemente R, Ferracane C, Shahini E, Mendolaro M, Grossi L, Mazzuoli S, Rispo A, Pranzo G, Sebkova L, Tursi A, Miranda A, Patturelli M, Spagnuolo R, Ricciardelli C, Sgarro C, Paese P, Inserra G, Azzarone A, Nardone O, Fries W, Buccianti N, Privitera AC, Principi MB, Cappello M, Guglielmi FW, Romano M, Riegler G, Fanigliulo L, Melina…

Read More

Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis.

ibdwatch

Related Articles Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis. Gastroenterology. 2019 Nov 08;: Authors: Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, Kühbacher T, Yacyshyn B, Cabell CH, Naik SU, Klassen P, Panés J Abstract BACKGROUND AND AIMS: Etrasimod (APD334) is an oral, selective sphingosine 1-phosphate receptor modulator in development for immune-mediated inflammatory disorders. We assessed the efficacy and safety of etrasimod in patients with moderately to severely active ulcerative colitis (UC). METHODS: In a phase 2,…

Read More
<< Go Back